LumiThera, a Poulsbo-based medical device company specializing in ocular disease treatments, has received FDA clearance for the first-ever light-based therapy for dry age-related macular degeneration (AMD).
Utilizing photobiomodulation, which uses different wavelengths of light to stimulate retinal cell activity, LumiThera’s Valeda system treats dry AMD, a leading cause of blindness in adults over age 65. “We now have a non-invasive treatment option for dry AMD patients that may improve vision and address the disease earlier before permanent vision loss,” said Clark Tedford, CEO of LumiThera.
LumiThera’s FDA clearance adds to Washington state’s established reputation for developing cutting-edge medical technologies.